These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 35173991)

  • 21. Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma.
    Radocha J; van de Donk NWCJ; Weisel K
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin.
    Lu R; Morphey A; Diaz F; Chen J; Razmandi A; Richards T
    J Adv Pract Oncol; 2023 May; 14(4):300-306. PubMed ID: 37313276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Belantamab mafodotin for relapsed or refractory multiple myeloma.
    Gil-Sierra MD; Briceño-Casado MDP
    J Oncol Pharm Pract; 2022 Sep; 28(6):1375-1380. PubMed ID: 35306910
    [No Abstract]   [Full Text] [Related]  

  • 24. Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin.
    Springer C; Krauter J; Trummer A
    Oncotarget; 2023 Dec; 14():949-956. PubMed ID: 38039414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
    Nooka AK; Cohen AD; Lee HC; Badros A; Suvannasankha A; Callander N; Abdallah AO; Trudel S; Chari A; Libby EN; Chaudhry M; Hultcrantz M; Kortüm KM; Popat R; Sborov D; Hakim S; Lewis E; Gorsh B; Bhushan B; McKeown A; Gupta I; Opalinska J; Richardson PG; Lonial S
    Cancer; 2023 Dec; 129(23):3746-3760. PubMed ID: 37622738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.
    de la Rubia J; Alonso R; Clavero ME; Askari E; García A; Antón C; Fernández M; Escalante F; García A; Rios-Tamayo R; Conesa V; Bermúdez MA; Merchán B; Velasco AE; Blanchard MJ; Sampol A; Gainza E; Hernández PM; Alegre A
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor.
    Joseph NS; Tai YT; Anderson KC; Lonial S
    Clin Pharmacol; 2021; 13():169-180. PubMed ID: 34434061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
    Nooka AK; Weisel K; van de Donk NW; Routledge D; Otero PR; Song K; Quach H; Callander N; Minnema MC; Trudel S; Jackson NA; Ahlers CM; Im E; Cheng S; Smith L; Hareth N; Ferron-Brady G; Brouch M; Montes de Oca R; Paul S; Holkova B; Gupta I; Kremer BE; Richardson P
    Future Oncol; 2021 Jun; 17(16):1987-2003. PubMed ID: 33682447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
    Sanchez L; Dardac A; Madduri D; Richard S; Richter J
    Ther Adv Hematol; 2021; 12():2040620721989585. PubMed ID: 33796236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
    Shragai T; Magen H; Lavi N; Gatt M; Trestman S; Zektser M; Ganzel C; Jarchowsky O; Berger T; Tadmor T; Leiba M; Hertzog-Tzarfaty K; Horowitz N; Shapira M; Varssano D; Berger Y; Frenkel S; Krauthammer M; Avivi I; Luttwak E; Cohen YC;
    Br J Haematol; 2023 Jan; 200(1):45-53. PubMed ID: 36205375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
    Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Sborov D; Suvannasankha A; Weisel K; Voorhees PM; Womersley L; Baron J; Piontek T; Lewis E; Opalinska J; Gupta I; Cohen AD
    Cancer; 2021 Nov; 127(22):4198-4212. PubMed ID: 34314018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience.
    Iula R; De Novellis D; Trastulli F; Della Pepa R; Fontana R; Carobene A; Di Perna M; D'Ambrosio A; Romano M; Leone A; De Fazio L; Fiumarella A; Gaeta G; Marafioti V; Barbato S; Palmieri S; Rocco S; Serio B; Califano C; Pane F; Ferrara F; Giudice V; Selleri C; Catalano L
    Front Oncol; 2022; 12():1026251. PubMed ID: 36457484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models.
    Singh RK; Jones RJ; Shirazi F; Qin L; Zou J; Hong S; Wang H; Lee HC; Patel KK; Wan J; Choudhary RK; Kuiatse I; Pahl A; Orlowski RZ
    Res Sq; 2024 Jan; ():. PubMed ID: 38260385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
    Demel I; Bago JR; Hajek R; Jelinek T
    Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma.
    McCurdy A; Visram A
    Curr Hematol Malig Rep; 2022 Dec; 17(6):306-318. PubMed ID: 36417082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
    Ray U; Orlowski RZ
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy.
    Fazio F; Petrucci MT; Corvatta L; Piciocchi A; Della Pepa R; Tacchetti P; Musso M; Zambello R; Belotti A; Bringhen S; Antonioli E; Conticello C; Renzo ND; De Stefano V; Musto P; Gamberi B; Derudas D; Boccadoro M; Offidani M; Morè S
    EJHaem; 2024 Jun; 5(3):485-493. PubMed ID: 38895069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond.
    Podar K; Leleu X
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Effect of Belantamab Mafodotin on Primary Myeloma-Stroma Co-Cultures: Asymmetrical Mitochondrial Transfer between Myeloma Cells and Autologous Bone Marrow Stromal Cells.
    Matula Z; Uher F; Vályi-Nagy I; Mikala G
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982377
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.